A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of GR2002 Injection in Patients With Moderate to Severe Atopic Dermatitis
Latest Information Update: 20 Dec 2023
At a glance
- Drugs GR 2002 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Genrix (Shanghai) Biopharmaceuticals
Most Recent Events
- 20 Dec 2023 New trial record